ChemoCentryx Company Profile (NASDAQ:CCXI)

About ChemoCentryx

ChemoCentryx logoChemoCentryx, Inc. (ChemoCentryx) is a biopharmaceutical company. The Company is focused on discovering, developing and commercializing orally-administered therapeutics to treat orphan and rare diseases, autoimmune diseases, inflammatory disorders and cancer. It targets the chemoattractant system, which is a network of molecules, including chemokine ligands and their associated receptors, as well as related chemoattractant receptors. Each of its drug candidates is a small molecule designed to target a specific chemokine or chemoattractant receptor, thereby blocking the negative inflammatory or suppressive response driven by that particular receptor, while leaving the rest of the immune system intact. The Company's pipeline comprises various programs, including orphan and rare diseases, immuno-oncology, chronic kidney disease, and other inflammatory and autoimmune diseases.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: Biotechnology
  • Exchange: NASDAQ
  • Symbol: CCXI
  • CUSIP: 16383L10
Key Metrics:
  • Previous Close: $6.25
  • 50 Day Moving Average: $5.42
  • 200 Day Moving Average: $4.46
  • 52-Week Range: $47,762,000.00 - $1.92
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -5.95
  • P/E Growth: 0.00
  • Market Cap: $298.51M
  • Outstanding Shares: 47,762,000
  • Beta: 1.42
  • Return on Equity: -70.89%
  • Return on Assets: -51.68%
  • Current Ratio: 5.54%
  • Quick Ratio: 5.54%
Additional Links:
Companies Related to ChemoCentryx:

Analyst Ratings

Consensus Ratings for ChemoCentryx (NASDAQ:CCXI) (?)
Ratings Breakdown: 1 Hold Rating, 1 Buy Rating
Consensus Rating:Buy (Score: 2.50)
Consensus Price Target: $11.00 (76.00% upside)

Analysts' Ratings History for ChemoCentryx (NASDAQ:CCXI)
DateFirmActionRatingPrice TargetDetails
8/9/2016JPMorgan Chase & Co.Reiterated RatingBuy$11.00View Rating Details
5/19/2016Cowen and CompanyReiterated RatingHoldView Rating Details
(Data available from 10/23/2014 forward)


Earnings History for ChemoCentryx (NASDAQ:CCXI)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
5/10/2016Q1($0.27)($0.34)ViewListenView Earnings Details
3/14/2016Q4($0.28)($0.26)ViewN/AView Earnings Details
11/9/2015Q315($0.29)($0.26)ViewListenView Earnings Details
8/6/2015Q215($0.29)($0.28)ViewN/AView Earnings Details
5/6/2015Q115($0.28)($0.28)ViewListenView Earnings Details
3/12/2015Q414($0.28)($0.28)ViewListenView Earnings Details
11/5/2014($0.28)($0.25)ViewN/AView Earnings Details
5/8/2014Q114($0.24)($0.27)$0.38 millionViewN/AView Earnings Details
3/13/2014($0.25)($0.22)ViewN/AView Earnings Details
8/12/2013Q2 2013($0.28)($0.23)$1.48 million$1.90 millionViewN/AView Earnings Details
5/13/2013Q1 2013($0.27)($0.28)$2.04 million$1.90 millionViewN/AView Earnings Details
11/13/2012Q312($0.28)$1.44 million$1.13 millionViewN/AView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for ChemoCentryx (NASDAQ:CCXI)
Current Year EPS Consensus Estimate: $-0.89 EPS
Next Year EPS Consensus Estimate: $-1.05 EPS


Dividend History for ChemoCentryx (NASDAQ:CCXI)
No dividend announcements for this company have been tracked by

Insider Trades

Insider Trading History for ChemoCentryx (NASDAQ:CCXI)
Insider Ownership Percentage: 26.80%
Institutional Ownership Percentage: 47.80%
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
9/1/2016Roger C LucasDirectorSell4,000$5.07$20,280.00View SEC Filing  
5/23/2016James L TyreeDirectorSell5,544$4.39$24,338.16View SEC Filing  
5/17/2016Thomas A EdwardsDirectorBuy50,000$4.05$202,500.00View SEC Filing  
5/16/2016Thomas A EdwardsDirectorBuy25,000$4.05$101,250.00View SEC Filing  
5/13/2016Geoffrey M ParkerDirectorBuy40,000$4.03$161,200.00View SEC Filing  
1/22/2016Susan M. KanayaCFOSell25,764$4.04$104,086.56View SEC Filing  
1/20/2016Susan M. KanayaCFOSell14,971$4.10$61,381.10View SEC Filing  
1/19/2016Susan M. KanayaCFOSell6,134$4.05$24,842.70View SEC Filing  
1/15/2016Susan M. KanayaCFOSell300$4.00$1,200.00View SEC Filing  
1/11/2016Geoffrey M ParkerDirectorBuy20,000$4.63$92,600.00View SEC Filing  
1/8/2016Susan M. KanayaCFOSell10,224$5.12$52,346.88View SEC Filing  
1/6/2016Susan M. KanayaCFOSell47,607$6.98$332,296.86View SEC Filing  
1/5/2016Susan M. KanayaCFOSell34,341$6.90$236,952.90View SEC Filing  
1/4/2016Susan M. KanayaCFOSell10,490$7.38$77,416.20View SEC Filing  
12/11/2015Geoffrey M ParkerDirectorBuy20,000$7.25$145,000.00View SEC Filing  
11/4/2015Value Fund L P BiotechnologyInsiderSell360,000$7.00$2,520,000.00View SEC Filing  
11/2/2015Value Fund L P BiotechnologyInsiderSell50,000$6.97$348,500.00View SEC Filing  
6/10/2015Bvf Partners L P/IlMajor ShareholderSell955,700$9.00$8,601,300.00View SEC Filing  
5/22/2015Ira KleinDirectorSell10,811$7.44$80,433.84View SEC Filing  
4/1/2015Thomas J SchallCEOSell24,267$7.50$182,002.50View SEC Filing  
3/31/2015Thomas J SchallCEOSell16,540$7.55$124,877.00View SEC Filing  
3/30/2015Thomas J SchallCEOSell1,200$7.51$9,012.00View SEC Filing  
3/24/2015Thomas J SchallCEOSell50,371$7.84$394,908.64View SEC Filing  
3/19/2015Thomas J SchallCEOSell18,146$8.34$151,337.64View SEC Filing  
3/17/2015Thomas J SchallCEOSell31,316$8.55$267,751.80View SEC Filing  
3/9/2015Markus J CappelTreasurerSell34,125$7.81$266,516.25View SEC Filing  
3/4/2015Markus J CappelTreasurerSell40,875$7.98$326,182.50View SEC Filing  
3/3/2015Markus J CappelTreasurerSell5,943$7.81$46,414.83View SEC Filing  
3/2/2015Markus J CappelTreasurerSell14,390$8.13$116,990.70View SEC Filing  
11/18/2014Anne-Marie DuliegeEVPSell4,970$4.71$23,408.70View SEC Filing  
5/1/2014Thomas J SchallCEOSell27,726$5.59$154,988.34View SEC Filing  
4/29/2014Thomas J SchallCEOSell32,274$5.38$173,634.12View SEC Filing  
4/22/2014Markus J CappelTreasurerSell20,962$8.17$171,259.54View SEC Filing  
3/17/2014Thomas J SchallCEOSell20,000$7.25$145,000.00View SEC Filing  
12/6/2013Geoffrey M ParkerDirectorBuy20,000$5.15$103,000.00View SEC Filing  
12/5/2013Bvf Partners L P/IlMajor ShareholderBuy189,800$5.01$950,898.00View SEC Filing  
11/6/2013Bvf Partners L P/IlMajor ShareholderBuy136,066$4.92$669,444.72View SEC Filing  
11/1/2013Bvf Partners L P/IlMajor ShareholderBuy336,225$4.99$1,677,762.75View SEC Filing  
10/9/2013Bvf Partners L P/IlMajor ShareholderBuy1,289,354$5.34$6,885,150.36View SEC Filing  
10/3/2013Bvf Partners L P/IlMajor ShareholderBuy109,425$5.49$600,743.25View SEC Filing  
9/13/2013Bvf Partners L P/IlMajor ShareholderBuy325,635$5.95$1,937,528.25View SEC Filing  
9/13/2013Joseph M FeczkoDirectorBuy10,000$6.03$60,300.00View SEC Filing  
8/13/2013Markus J CappelTreasurerSell5,459$12.90$70,421.10View SEC Filing  
8/7/2013Petrus BekkerSVPSell5,000$13.26$66,300.00View SEC Filing  
8/5/2013Roger C LucasDirectorSell5,000$13.42$67,100.00View SEC Filing  
8/1/2013Markus J CappelTreasurerSell6,250$13.82$86,375.00View SEC Filing  
7/17/2013Markus J CappelTreasurerSell5,459$14.52$79,264.68View SEC Filing  
7/17/2013Petrus BekkerSVPSell10,000$14.54$145,400.00View SEC Filing  
7/16/2013Thomas J SchallCEOSell22,089$14.39$317,860.71View SEC Filing  
7/3/2013Roger C LucasDirectorSell5,000$13.43$67,150.00View SEC Filing  
7/2/2013Markus J CappelTreasurerSell6,250$13.88$86,750.00View SEC Filing  
6/28/2013Susan M KanayaCFOSell36,942$14.31$528,640.02View SEC Filing  
6/27/2013Petrus BekkerSVPSell5,000$14.00$70,000.00View SEC Filing  
6/21/2013Markus J CappelTreasurerSell6,250$13.00$81,250.00View SEC Filing  
6/18/2013Markus J CappelTreasurerSell1,783$12.47$22,234.01View SEC Filing  
6/17/2013Petrus BekkerSVPSell5,000$12.00$60,000.00View SEC Filing  
6/3/2013Roger C LucasDirectorSell5,000$13.32$66,600.00View SEC Filing  
5/30/2013Susan M KanayaCFOSell12,770$14.28$182,355.60View SEC Filing  
5/28/2013Markus J CappelTreasurerSell3,676$14.10$51,831.60View SEC Filing  
5/24/2013Petrus BekkerSVPSell4,800$14.00$67,200.00View SEC Filing  
5/17/2013Petrus BekkerSVPSell15,000$13.97$209,550.00View SEC Filing  
5/15/2013Markus J CappelTreasurerSell15,668$14.08$220,605.44View SEC Filing  
5/15/2013Roger C LucasDirectorSell5,000$14.11$70,550.00View SEC Filing  
5/15/2013Thomas J SchallCEOSell7,600$14.04$106,704.00View SEC Filing  
4/11/2013Markus J CappelTreasurerSell1,500$14.10$21,150.00View SEC Filing  
4/11/2013Petrus BekkerSVPSell3,979$14.03$55,825.37View SEC Filing  
4/11/2013Thomas J SchallCEOSell2,529$14.02$35,456.58View SEC Filing  
3/6/2013Petrus BekkerSVPSell11,502$13.98$160,797.96View SEC Filing  
3/6/2013Thomas J SchallCEOSell5,541$14.01$77,629.41View SEC Filing  
3/4/2013Roger C LucasDirectorSell5,000$13.87$69,350.00View SEC Filing  
2/26/2013Juan C JaenSVPSell22,500$12.23$275,175.00View SEC Filing  
2/22/2013Thomas J SchallCEOSell7,500$12.06$90,450.00View SEC Filing  
2/6/2013Roger C LucasDirectorSell3,857$11.52$44,432.64View SEC Filing  
2/4/2013Juan C JaenSVPSell3,875$11.69$45,298.75View SEC Filing  
1/17/2013Markus J CappelTreasurerSell2,700$11.16$30,132.00View SEC Filing  
11/6/2012Bvf Partners L P/IlMajor ShareholderBuy40,000$12.00$480,000.00View SEC Filing  
10/4/2012Roger C LucasDirectorSell1,893$11.47$21,712.71View SEC Filing  
10/1/2012Susan M KanayaCFOSell3,971$11.89$47,215.19View SEC Filing  
10/1/2012Thomas J SchallCEOSell15,000$11.53$172,950.00View SEC Filing  
(Data available from 1/1/2013 forward)


Latest Headlines for ChemoCentryx (NASDAQ:CCXI)
News Icon15006 Shares of ChemoCentryx Inc. (CCXI) are sold by California State Teachers Retirement System - DailyQuint (NASDAQ:CCXI) - October 22 at 8:25 AM logoChemoCentryx : Appoints Henry A. McKinnell, Jr. to Board of Directors (NASDAQ:CCXI) - October 21 at 4:10 PM logoChemoCentryx, Inc., (NASDAQ:CCXI) Files An 8-K - Market Exclusive - Market Exclusive (NASDAQ:CCXI) - October 21 at 12:26 PM
News IconGodt nyt : tidligere CEO pfizer ny i bestyrelsen - blåstempling (NASDAQ:CCXI) - October 20 at 9:02 PM logoChemoCentryx Appoints Henry A. McKinnell, Jr. to Board of Directors - GlobeNewswire (press release) (NASDAQ:CCXI) - October 20 at 3:38 PM logoCHEMOCENTRYX, INC. Files SEC form 8-K, Change in Directors or Principal Officers, Regulation FD Disclosure, Financial (NASDAQ:CCXI) - October 20 at 3:38 PM logoChemoCentryx : ChemoCentryxs CCR2 Inhibitor CCX872 Shown to Reduce Liver Fibrosis in NASH Models (NASDAQ:CCXI) - October 20 at 8:57 AM logoChemoCentryx Appoints Henry A. McKinnell, Jr. to Board of Directors (NASDAQ:CCXI) - October 20 at 8:57 AM
News IconStock Flexing Muscles Mid-session: ChemoCentryx, Inc. (NASDAQ ... - CSZ News (NASDAQ:CCXI) - October 19 at 9:02 AM logoChemoCentryx (CCXI) Announces Significant Data from CCX872 In Vivo Models of NASH (NASDAQ:CCXI) - October 18 at 4:04 PM logoChemoCentryx (CCXI) Announces Significant Data from CCX872 In Vivo Models of NASH - (NASDAQ:CCXI) - October 18 at 9:07 AM logoChemoCentryx (CCXI) to Present Positive CCX168 Phase 2 Data at ASN Kidney Week 2016 - (NASDAQ:CCXI) - October 18 at 9:07 AM logoChemoCentryx’s CCR2 Inhibitor CCX872 Shown to Reduce Liver Fibrosis in NASH Models (NASDAQ:CCXI) - October 18 at 9:07 AM logoTreatment of aHUS patients with CCX168 effective in reducing aHUS serum-induced thrombus formation (NASDAQ:CCXI) - October 17 at 8:59 AM logoChemoCentryx Announces Presentation of Positive Data from Ongoing Pilot Phase II Trial of CCX168 (Avacopan) in Atypical Hemolytic Uremic Syndrome (aHUS) at ASN Kidney Week 2016 (NASDAQ:CCXI) - October 17 at 8:59 AM
News IconForging Higher Over Past 6-Months, Can It Continue For ChemoCentryx, Inc. (NASDAQ:CCXI) - CSZ News (NASDAQ:CCXI) - October 16 at 4:02 PM
News IconChemoCentryx, Inc. (NASDAQ:CCXI) Updated Broker Ratings - NewsDen (NASDAQ:CCXI) - October 16 at 8:51 AM
News IconShort Interest Report: Chemocentryx Incorporated (NASDAQ:CCXI) Shorted Shares Increased By 0.96% - Post News (NASDAQ:CCXI) - October 14 at 4:01 PM
News IconLatest Analyst Ratings For ChemoCentryx, Inc. (NASDAQ:CCXI ... - The De Soto Edge (NASDAQ:CCXI) - October 3 at 4:00 PM
News IconAnalyst Review: ChemoCentryx, Inc. (NASDAQ:CCXI) - NewsDen (NASDAQ:CCXI) - October 3 at 8:56 AM
News IconSå brød CCXI .Hedgefond ind ...bruddet op (NASDAQ:CCXI) - September 27 at 4:04 PM logoHealthcare-Focused Michael Castor Added These Stocks to His Portfolio Last Quarter (NASDAQ:CCXI) - September 27 at 8:43 AM
News IconOn the Move Insider Trading: ChemoCentryx Inc (NASDAQ:CCXI ... - Post Registrar (NASDAQ:CCXI) - September 7 at 9:25 AM
News IconChemoCentryx Inc (NASDAQ:CCXI): Here’s Our Take (NASDAQ:CCXI) - September 6 at 9:03 PM
News IconAverage Price Target for ChemoCentryx, Inc. (NASDAQ:CCXI) is $11 - Newburg Press (NASDAQ:CCXI) - September 6 at 4:01 PM
News IconBiotech news that matter for investors: ChemoCentryx, Inc. (NASDAQ:CCXI), Dynavax Technologies Corporation ... - The Voice Registrar (NASDAQ:CCXI) - September 6 at 4:01 PM
News IconChemoCentryx Inc (NASDAQ:CCXI): Here's Our Take - Street Register (NASDAQ:CCXI) - September 6 at 4:01 PM
News IconActive Biotech Stock News: ChemoCentryx, Inc. (CCXI), Threshold Pharmaceuticals Inc. (THLD) - The Independent Republic (NASDAQ:CCXI) - September 6 at 8:57 AM
News IconNASDAQ Composite Index Rises Again after Markets Digest Payrolls Data (NASDAQ:CCXI) - September 3 at 8:47 AM logoMid-Day Market Update: Crude Oil Up 3%; VeriFone Shares Decline On Lowered Forecast (NASDAQ:CCXI) - September 2 at 3:56 PM logoMid-Afternoon Market Update: Accuride Jumps Following Acquisition Announcement; Lululemon Shares Slide (NASDAQ:CCXI) - September 2 at 3:56 PM logoChemoCentryx (CCXI) Announces Interim ORR Data from CCX872 Phase 1b in Adv. Pancreatic Cancer (NASDAQ:CCXI) - September 2 at 3:56 PM logoWhy ChemoCentryx Inc (NASDAQ:CCXI) Tanked Today (NASDAQ:CCXI) - September 2 at 3:56 PM logoChemoCentryx's CCX872 appears safe in early-stage pancreatic cancer study; shares off 10% premarket (NASDAQ:CCXI) - September 2 at 9:27 AM logoChemoCentryx (CCXI) Announces Interim ORR Data from CCX872 Phase 1b in Adv. Pancreatic Cancer - (NASDAQ:CCXI) - September 2 at 8:56 AM logoChemoCentryx Reports Initial Results from Ongoing Phase Ib Clinical Trial of CCX872 in Patients with Advanced Pancreatic Cancer (NASDAQ:CCXI) - September 2 at 8:56 AM logo4:09 pm ChemoCentryx announces initial 12 week overall response rate results from an ongoing open label, single arm Phase Ib clinical trial with CCX872 in patients with advanced pancreatic cancer (NASDAQ:CCXI) - September 2 at 8:56 AM
News IconStock on the Rise in Session: ChemoCentryx, Inc. (NASDAQ:CCXI) - Post News (NASDAQ:CCXI) - August 31 at 4:03 PM logoChemoCentryx to Present at the Baird 2016 Global Healthcare Conference (NASDAQ:CCXI) - August 25 at 8:59 AM logoCHEMOCENTRYX, INC. Financials (NASDAQ:CCXI) - August 17 at 4:14 PM logoChemoCentryx, Inc. (CCXI) (NASDAQ:CCXI) - August 15 at 9:45 PM logoCHEMOCENTRYX, INC. Files SEC form 10-Q, Quarterly Report (NASDAQ:CCXI) - August 9 at 4:24 PM logoEdited Transcript of CCXI earnings conference call or presentation 8-Aug-16 9:00pm GMT (NASDAQ:CCXI) - August 9 at 4:24 PM logoChemoCentryx reports 2Q loss (NASDAQ:CCXI) - August 8 at 9:34 PM logoChemoCentryx Reports Second Quarter 2016 Financial Results and Provides Corporate Update (NASDAQ:CCXI) - August 8 at 4:13 PM logoQ2 2016 ChemoCentryx Inc Earnings Release - After Market Close (NASDAQ:CCXI) - August 8 at 8:57 AM logoChemoCentryx, Inc. (NASDAQ:CCXI) Updated Price Targets - FTSE ... - FTSE News (NASDAQ:CCXI) - August 2 at 8:56 AM logoChemoCentryx to Hold Second Quarter 2016 Financial Results Conference Call on Monday, August 8, 201 (NASDAQ:CCXI) - August 1 at 8:58 AM logoChemoCentryx to Hold Second Quarter 2016 Financial Results Conference Call on Monday, August 8, 2016 (NASDAQ:CCXI) - August 1 at 8:30 AM
News IconInsiders Increasing Positions in: ChemoCentryx, Inc. (NASDAQ:CCXI) - Press Telegraph (NASDAQ:CCXI) - July 21 at 8:01 AM


ChemoCentryx (NASDAQ:CCXI) Chart for Sunday, October, 23, 2016

Last Updated on 10/23/2016 by Staff